Clinical Report: Erroneous eTable 9 in Supplement 1 Corrected

Overview

This report addresses the correction of an error in the supplemental content of the original investigation on SGLT2 inhibitors and hyperkalemia risk. The erroneous eTable 9 has been replaced with the correct table.

Background

Accurate data presentation in clinical research is crucial for informed decision-making in patient care. Errors in published tables can lead to misinterpretation of study findings.

Data Highlights

No numerical or trial data is presented in this correction article.

Key Findings

• The original publication contained a duplicate of eTable 10 instead of the correct eTable 9.
• Corrections ensure that the data presented aligns with the study's findings on SGLT2 inhibitors and hyperkalemia risk.

Clinical Implications

Healthcare professionals should be aware of the importance of verifying data accuracy in clinical studies. This correction serves as a reminder to consult the most recent and corrected versions of published research when making clinical decisions.

Conclusion

The correction of eTable 9 reinforces the necessity for accuracy in clinical research publications. Ensuring correct data representation is vital for effective patient management and adherence to clinical guidelines.

Related Resources & Content

1. SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors, JAMA Internal Medicine, 2025 -- Original Investigation
2. Journal of Gastroenterology — Erratum: Relationship Between Composite Detection Rates in Upper Gastrointestinal Endoscopy and Neoplasia Identification
3. Drug Safety — Erratum: Safety Profile of Onasemnogene Abeparvovec in Clinical Trials and Postmarketing Surveillance
4. Erratum: Compliance with Multi-Target Stool DNA Testing for Colorectal Cancer Screening in the U.S.
5. Gastric Cancer — Amendment to: Importance of Intratumoral HER2 Variability on Trastuzumab Effectiveness in Advanced HER2 Positive Gastric Cancer Patients Analyzed via Endoscopic Biopsy Samples
6. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
7. SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors
8. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial | JACC